Global digital dose inhaler market is anticipated to grow at a considerable CAGR of 7.3% during the forecast period (2024-2031). Digital dose inhalers are increasingly used in respiratory care to improve medication adherence, disease management, and patient outcomes. It tracks medication use, provides real-time data, and offers reminder systems to help patients follow their prescribed regimens. It additionally offers usage feedback and educational resources to patients, enabling remote monitoring and telemedicine consultations. Digital dose inhalers additionally generate vast data, which can be analyzed for trends and personalized treatment strategies. They can be integrated with electronic health records to facilitate comprehensive patient care and improve communication between care teams. They also play an essential role in respiratory research and clinical trials. Furthermore, the market has seen significant growth primarily owing to increased focus on R&D by both public and private organizations and growing applications. For instance,
Browse the full report description of “Digital Dose Inhaler Market Size, Share & Trends Analysis Report by Product (Dry Powder Inhalers, and Metered Dose Inhalers), by Application (Chronic Obstructive Pulmonary Disease, Asthma, and Others). by Type (Branded, and Generic). and by End Users (Hospitals, Homecare Settings, and Others). Forecast Period (2024-2031).” at https://www.omrglobal.com/industry-reports/digital-dose-inhaler-market
In June 2023, Phil Inc. partnered with Teva Pharmaceuticals to make Digihaler products available for prescription using the PhilRx Patient Access Platform. The platform provides end-to-end visibility into the entire prescription life cycle, allowing physicians to submit prescriptions and develop personalized care plans based on the data provided. The partnership aims to enable patients to receive and refill their Digihaler medication quickly, easily, and affordably.
In February 2022, Aptar Pharma launched HeroTracker Sense, a digital respiratory health solution that transforms standard metered dose inhalers into smart connected healthcare devices. The device helps patients with chronic respiratory diseases like asthma, COPD, and Cystic Fibrosis track their MDI usage and improve adherence to therapy.
In September 2020, Teva Respiratory launched two new digital inhaler products, the AirDuo Digihaler, and the ArmonAir Digihaler, for treating asthma patients aged 12 and older. These prescription inhalation powders control and prevent symptoms, but are not intended for sudden breathing problems.
The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Product
o By Application
o By Type
o By End User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Koninklijke Philips N.V., and Merck & Co., Inc., among others.
Key questions addressed by the report.
Global Digital Dose Inhaler Market Report Segment
By Product
By Application
By Type
By End-User
Global Digital Dose Inhaler Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/digital-dose-inhaler-market